Reviewed by Michael Gill, B. Sc.
21 Diffuse Large B Cell Lymphoma Clinical Trials Near Me
Top Hospitals for Diffuse Large B Cell Lymphoma Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
4Active Trials
50All Time Trials for Diffuse Large B Cell Lymphoma
2003First Diffuse Large B Cell Lymphoma Trial
Image of Northwestern University in Illinois.
Northwestern University
Chicago
4Active Trials
22All Time Trials for Diffuse Large B Cell Lymphoma
2006First Diffuse Large B Cell Lymphoma Trial
Diffuse Large B Cell Lymphoma Clinical Trials by Phase of Trial
Most Recent Diffuse Large B Cell Lymphoma Clinical Trials
Top Treatments for Diffuse Large B Cell Lymphoma Clinical Trials
Treatment Name
Active Diffuse Large B Cell Lymphoma Clinical Trials
All Time Trials for Diffuse Large B Cell Lymphoma
First Recorded Diffuse Large B Cell Lymphoma Trial
Pembrolizumab
2
25
2013
lisocabtagene maraleucel
2
2
2018
CC-122
2
4
2011
Digital Health Coaching
1
1
2022
Venetoclax
1
21
2016
Recently Completed Studies with FDA Approved Treatments for Diffuse Large B Cell Lymphoma
Treatment
Year
Sponsor
PRT543
2019
Prelude Therapeutics
AMG 562
2018
Amgen
TRPH-222
2018
Triphase Research and Development III Corp.
Loncastuximab tesirine
2018
ADC Therapeutics S.A.
CDX-1140
2017
Celldex Therapeutics
Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
2017
Masonic Cancer Center, University of Minnesota
Cord Blood-derived Expanded Allogeneic Natural Killer Cells
2017
M.D. Anderson Cancer Center
PLX2853
2017
Plexxikon
Anti-CD30-CAR T cells
2017
National Cancer Institute (NCI)
Durvalumab
2017
Celgene

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. https://pubmed.ncbi.nlm.nih.gov/15939142 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30. https://pubmed.ncbi.nlm.nih.gov/189296863 Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9:CD013365. doi: 10.1002/14651858.CD013365.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/345153384 Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. https://pubmed.ncbi.nlm.nih.gov/251137535 Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. https://pubmed.ncbi.nlm.nih.gov/251137536 Del Pozo Martín Y. 2021 ASH annual meeting. Lancet Haematol. 2022 Feb;9(2):e92-e93. doi: 10.1016/S2352-3026(21)00384-7. Epub 2021 Dec 16. https://pubmed.ncbi.nlm.nih.gov/349226487 Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20. https://pubmed.ncbi.nlm.nih.gov/301252158 Madore S, Kilbourn K, Valverde P, Borrayo E, Raich P. Feasibility of a psychosocial and patient navigation intervention to improve access to treatment among underserved breast cancer patients. Support Care Cancer. 2014 Aug;22(8):2085-93. doi: 10.1007/s00520-014-2176-5. Epub 2014 Mar 18. https://pubmed.ncbi.nlm.nih.gov/246390359 Girault A, Ferrua M, Lalloué B, Sicotte C, Fourcade A, Yatim F, Hébert G, Di Palma M, Minvielle E. Internet-based technologies to improve cancer care coordination: current use and attitudes among cancer patients. Eur J Cancer. 2015 Mar;51(4):551-557. doi: 10.1016/j.ejca.2014.12.001. Epub 2015 Feb 4. https://pubmed.ncbi.nlm.nih.gov/2566182810 Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T 3rd, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):246-256.e2. doi: 10.1016/j.clml.2020.11.005. Epub 2020 Nov 11. https://pubmed.ncbi.nlm.nih.gov/33288485